Search
cemiplimab (Libtayo)
Indications:
- advanced cutanous squamous cell carcinoma
- advanced cutanous basal cell carcinoma previously treated with hedgehog pathway inhibitor
Dosage:
- 3 mg/kg every 2 weeks
Adverse effects:
- discontinuation in 13%
- pneumonitis, hypothyroidism, arthralgia, vitiligo common with PD-1 inhibitors [2]
- fatigue, somnolence, musculoskeletal pain
- rash, pruritus, infected neoplasm
- upper respiratory tract infection
- urinary tract infection, acute kidney injury
- colitis, diarrhea
- adrenal insufficiency
- anemia
Mechanism of action:
- inhibits PD-1 pathway
Interactions
drug adverse effects of checkpoint inhibitor(s)
General
antineoplastic monoclonal antibody
checkpoint inhibitor; immune checkpoint inhibitor; PD-1/PD-L1 inhibitor
References
- Kuznar W with expert critique by Klil-Drori AJ
Cemiplimab Gains Approval for Advanced Squamous Cell Carcinoma.
Durable responses with first systemic agent for this group of patients.
MedPage Today. ASCO Reading Room 10.27.2018.
https://www.medpagetoday.com/reading-room/asco/skin-cancer/75935
- Migden MR, Rischin D, Schmults CD et al
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell
Carcinoma.
N Engl J Med 2018; 379:341-351
PMID: 29863979
https://www.nejm.org/doi/full/10.1056/NEJMoa1805131
- Marin-Acevedo JA, Chirila RM, Dronca RS.
Immune Checkpoint Inhibitor Toxicities.
Mayo Clinic Proc. July 2019. 94(7):1321-1329
PMID: 31272574
- Bankhead C
First Immunotherapy Approved for Basal Cell Carcinoma -
Objective responses in 27% of previously treated patients who received cemiplimab.
MedPage Today February 10, 2021
https://www.medpagetoday.com/hematologyoncology/skincancer/91145